Several targeted inhibitors against BRAF mutations or other key components of MAPK pathway are emerging, but unfortunately, differently from other cancers, BRAFmt mCRCs resistance to single targeted-drug regimens is broadly attested in clinical practice. The gene discussed is BRAF; the disease is cancer.